Emmaus Life Sciences Secures Exclusive Supply Agreement for Endari® with NeoImmuneTech

summarizeSummary

Emmaus Life Sciences signed an exclusive supply agreement with NeoImmuneTech for Endari® in North America, with terms including a double-digit margin, though its effectiveness is contingent on regulatory approvals.

check_boxKey Events

• Exclusive Supply Agreement Signed

  Emmaus Life Sciences and NeoImmuneTech, Inc. (NIT) entered into an Exclusive Supply Agreement on March 2, 2026, for Endari® in the U.S. and Canada.

• Favorable Supply Terms

  Emmaus will exclusively supply Endari® to NIT, and NIT will exclusively purchase from Emmaus, at a price based on Emmaus's cost of production plus a specified double-digit percentage margin.

• Contingent Effective Date

  The agreement's 'Effective Date' is subject to NIT obtaining necessary regulatory approvals and licensing, with no assurance it will occur by the October 1, 2026 deadline.

• Follows Prior License Agreement

  This supply agreement was contemplated by a License and Exclusive Distribution Agreement dated December 24, 2025, previously reported on December 31, 2025.

auto_awesomeAnalysis

Emmaus Life Sciences has entered into an exclusive supply agreement with NeoImmuneTech (NIT) for its sickle cell disease product, Endari®, in the U.S. and Canada. This agreement, which was contemplated by a prior license agreement from December 2025, establishes Emmaus as the sole supplier to NIT at a purchase price based on production cost plus a double-digit percentage margin. While this deal could provide a stable revenue stream and distribution channel for Emmaus, its effectiveness is contingent upon NIT obtaining necessary regulatory approvals and licensing by October 1, 2026, introducing a degree of uncertainty.